BiotechTube
Home/Kala Pharmaceuticals/Meredith Kaya
MK

Meredith Kaya

Vice President, Clinical Development

Kala Pharmaceuticals

Therapeutic Areas

OphthalmologyRare Diseases

Kala Pharmaceuticals Pipeline

DrugIndicationPhase
KPI-012Persistent Corneal Epithelial Defect (PCED)Phase 2b
KPI-014Inherited Retinal DegenerationsPreclinical

Leadership Team at Kala Pharmaceuticals

MI
Mark Iwicki
Chairman, President and Chief Executive Officer
EL
Eric L. Trachtenberg
General Counsel and Secretary
KB
Kimberly Brown
Vice President, Operations
View full Kala Pharmaceuticals profile